{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:43:58Z","timestamp":1789454638744,"version":"build-2803163510"},"reference-count":35,"publisher":"American Society of Hematology","issue":"23","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Quadruplet regimens (anti-CD38 monoclonal antibodies [mAbs] with proteasome inhibitor [PI] and immunomodulatory drugs [IMiDs]) are increasingly being investigated in newly diagnosed multiple myeloma (NDMM). The objective of our study was to conduct a systematic review and meta-analysis to measure the efficacy and toxicity of quadruplet regimens used in NDMM. Embase, MEDLINE, Web of Science, Cochrane Library, clinical trial registries, and meeting libraries from inception to 24 January 2024, in addition to American Society of Clinical Oncology conference abstracts 2024, were searched using terms reflecting multiple myeloma and components of the quadruplet regimen. Included studies were randomized controlled trials (RCTs) that compared backbone regimens consisting of a PI and IMiD vs the same regimen plus an anti-CD38 mAb in NDMM. We identified 7 RCTs including 3716 patients. Compared with triplets, quadruplets increase the overall response rate (ORR; relative risk [RR], 1.03; 95% confidence interval [CI], 1.01-1.05) and progression-free survival (PFS; hazard ratio [HR], 0.55; 95%\u00a0CI, 0.46-0.66). Quadruplets increase the rates of minimal residual disease (MRD) negativity at 10\u20135 (RR, 1.39; 95%\u00a0CI, 1.23-1.58) and 10\u20136 (RR, 1.62; 95%\u00a0CI, 1.36-1.94). Quadruplets improve overall survival (OS; HR, 0.65; 95%\u00a0CI, 0.53-0.79). There was a slight increase in the rates of grade 3 to 4 infections (RR, 1.22; 95%\u00a0CI, 1.07-1.39) noted with quadruplets compared with triplets. Overall, in this meta-analysis, quadruplets were associated with improved efficacy including ORR, MRD negativity, PFS, and OS, with a slight increase in infection rates. Quadruplet regimens represent a new standard of care, particularly in transplant-eligible NDMM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014139","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T20:14:16Z","timestamp":1727727256000},"page":"5993-6002","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis"],"prefix":"10.1182","volume":"8","author":[{"given":"Mohammad S.","family":"Ebraheem","sequence":"first","affiliation":[{"name":"1Department of Oncology, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-3003","authenticated-orcid":false,"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"2Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"Rochwerg","sequence":"additional","affiliation":[{"name":"3Department of Medicine, McMaster University, Hamilton, ON, Canada"},{"name":"4Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Visram","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Ottawa Hospital Research Institute, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-783X","authenticated-orcid":false,"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Venner","sequence":"additional","affiliation":[{"name":"7Lymphoma and Myeloma Program, BC Cancer, Vancouver Centre, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9407-6265","authenticated-orcid":false,"given":"Irwindeep","family":"Sandhu","sequence":"additional","affiliation":[{"name":"8Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-4368","authenticated-orcid":false,"given":"Arleigh","family":"McCurdy","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Ottawa Hospital Research Institute, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Centre Hospitalier Universitaire Lille, University of Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"10Hematology Department, Hospital Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), Centro de Investigaci\u00f3n del C\u00e1ncer (IBMCC-USAL, CSIC), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Mian","sequence":"additional","affiliation":[{"name":"1Department of Oncology, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"issue":"8","key":"2024121014560791500_bib1","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"2","key":"2024121014560791500_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjh.17410","article-title":"Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology\/UK Myeloma Forum guideline","volume":"193","author":"Sive","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"2024121014560791500_bib3","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"issue":"10","key":"2024121014560791500_bib4","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"2024121014560791500_bib5","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"4","key":"2024121014560791500_bib6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"2024121014560791500_bib7","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2024121014560791500_bib8","author":"Facon","year":"2024"},{"key":"2024121014560791500_bib9","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","author":"Facon","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024121014560791500_bib10","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"32","key":"2024121014560791500_bib11","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"Cmaj"},{"key":"2024121014560791500_bib12","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2024121014560791500_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"suppl 1","key":"2024121014560791500_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the phase III randomized Iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2024121014560791500_bib15","first-page":"936","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"10192","key":"2024121014560791500_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"suppl 1","key":"2024121014560791500_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1182\/blood-2023-179866","article-title":"GEM2017FIT trial: induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus\/minus daratumumab (D), 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma (NDMM) patients aged between 65 and 80 years","volume":"142","author":"Mateos","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2024121014560791500_bib18","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2024121014560791500_bib19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2021-147897","article-title":"Daratumumab (DARA) with bortezomib, thalidomide, and dexamethasone (VTd) in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) negativity in Cassiopeia part 1 and part 2","volume":"138","author":"Avet Loiseau","year":"2021","journal-title":"Blood"},{"key":"2024121014560791500_bib20","author":"Hulin","year":"2019"},{"issue":"1","key":"2024121014560791500_bib21","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1186\/s12885-023-11507-9","article-title":"Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and-HD7 trials","volume":"23","author":"Kauer","year":"2023","journal-title":"BMC Cancer"},{"issue":"3","key":"2024121014560791500_bib22","doi-asserted-by":"crossref","first-page":"174.e1","DOI":"10.1016\/j.jtct.2022.11.029","article-title":"Stem cell mobilization yields with daratumumab-and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials","volume":"29","author":"Chhabra","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2024121014560791500_bib23","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"2024121014560791500_bib24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024121014560791500_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"key":"2024121014560791500_bib26","first-page":"2190","article-title":"Real-world treatment outcomes in patients with newly diagnosed multiple myeloma treated with triplet therapy without stem cell transplant: an enhanced electronic health records database","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2024121014560791500_bib27","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3390\/cells8121629","article-title":"The anti-CD38 antibody therapy in multiple myeloma","volume":"8","author":"Petrucci","year":"2019","journal-title":"Cells"},{"issue":"14","key":"2024121014560791500_bib28","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2024121014560791500_bib29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study","volume":"13","author":"Martin","year":"2023","journal-title":"Blood Cancer J"},{"issue":"23","key":"2024121014560791500_bib30","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood.2022016170","article-title":"MRD in multiple myeloma: does CR really matter?","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2024121014560791500_bib31","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"issue":"23","key":"2024121014560791500_bib32","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024121014560791500_bib33","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1634\/theoncologist.2017-0592","article-title":"Representation of minorities and elderly patients in multiple myeloma clinical trials","volume":"23","author":"Duma","year":"2018","journal-title":"Oncol"},{"key":"2024121014560791500_bib34","author":"Leleu","year":"2024"},{"issue":"5","key":"2024121014560791500_bib35","article-title":"Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant","volume":"5","author":"Langer","year":"2024","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/5993\/2345064\/blooda_adv-2024-014139-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/5993\/2345064\/blooda_adv-2024-014139-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T14:59:44Z","timestamp":1733842784000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/23\/5993\/518008\/Quadruplet-regimens-for-patients-with-newly"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":35,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014139","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]}}}